Robert Luxenhofer

​​Robert Luxenhofer completed his PhD in 2007 at the TU München in polymer chemistry developing a click chemistry and chemoselective functionalization of poly(2-oxazoline)s. This approach has since developed further by Serina Therapeutics to introduce the first-in-human

poly(2-oxazoline)-drug conjugates. 

​

As a postdoc with Alexander V. Kabanov at the University of Nebraska Medical Center, he discovered ultra-high loaded drug formulations and investigated structure-dependent endocytosis of poly(2-oxazoline) based amphiphiles. This discovery forms the foundation of DelAQUA Pharmaceuticals.

 

​Returning to Germany in 2009 for a habilitation, he started to investigate polysarcosine and polypeptoids as biomaterials at the TU Dresden as a Global Research Fellow of the King Abdullah University of Science and Technology. In 2012, he joined the Julius-Maximilians Universität as an Associate Professor, where he continued working on polypeptoids but also expanded the poly(2-oxazoline) formulations by including poly(2-oxazine)s, by which his team discovered intricate structure-property relationships in the corresponding ultra-high drug formulations. In addition, he started investigating biofabrication and 3D printing using melt electrowriting. 

​

In 2019, he joined the University of Helsinki as a Full Professor, and has since further expanded his research to in silico all-atoms molecular modelling of self-assembled biomaterials as well as gene-based therapies. He has supervised well over 100 undergrad and postgrad research projects and theses, published just little over 100 peer-reviewed publications (> 8000 citation) and has been granted 10  patents.